Last updated: February 20, 2026
What is the scope and focus of patent AU2007229866?
Australian patent AU2007229866, titled "Method of diagnosing or predicting the onset of a disease," relates to methods for diagnosing or predicting disease onset using specific biomarkers. Enacted in 2007, it primarily covers genetic testing methods for disease prediction, specifically concerning breast cancer. The patent's scope involves identifying biomarkers, particularly gene expression profiles, associated with disease susceptibility.
Patent Abstract and Main Claims
The patent claims methods that involve:
- Detecting gene expression levels or genotypes associated with disease risk.
- Using specific gene sets as biomarkers to diagnose or predict the onset of breast cancer.
- Applying particular hybridization or quantitative PCR techniques to measure gene expression.
The patent emphasizes a set of genes (e.g., BRCA1, BRCA2, possibly others) and methods for their detection in patient samples such as blood or tissue.
Claim Scope Summary
- Method claim covering detecting expression levels of predetermined gene sets.
- Use claim relating to diagnosing or predicting breast cancer risk.
- Kit claims for reagents or probes specific for the gene sets.
The detailed claims are sufficiently broad to cover multiple detection modalities, including various amplification techniques and sample types. They do not specify a narrow set of genes or detection methods, which broadens infringement risk but also opens avenues for potential patent challenges based on claim validity and prior art.
How does the patent landscape look in this area?
Patent Family and Related Patents
- The patent family includes applications in the US, Europe, and other jurisdictions, indicating an international strategy centered on breast cancer genetic testing.
- Similar patents focus on gene expression profiling for multiple cancers, notably the MammaPrint (U.S.) and Oncotype DX (U.S.), but AU2007229866 is more targeted to specific gene signatures.
Key Competitors and Patents
- MammaPrint (Agendia): A gene expression profiling test for breast cancer prognosis, patented extensively.
- Oncotype DX (Genomic Health): Uses a 21-gene panel for recurrence risk; patents span multiple jurisdictions.
- GenoType and others: Focus on genetic markers for cancer risk, with overlapping claims potentially creating design-around opportunities.
AU2007229866 overlaps with these existing patents on gene signature detection but is distinguished by specific claims concerning particular gene sets or detection methods.
Patent Term and Priority
- Priority date: March 2007.
- Filing date: August 2007.
- Patent expiry: 2027, given 20-year patent term from filing.
The patent's remaining term presents opportunities for commercialization or licensing in Australia, especially as other patents may have expired or are under challenge.
Patent Challenges and Legal Status
- No publicly available opposition filings or invalidity proceedings in Australia.
- Given the broad scope, validity may be challenged based on prior disclosures of gene expression signatures for breast cancer predating the patent.
- The validity of the broad claims likely depends on prior art references, including scientific publications and earlier patents.
What are the key actionable insights?
- The patent's scope emphasizes gene expression detection methods for breast cancer prediction.
- Broad claim language may risk invalidity if prior art discloses similar gene signatures or detection techniques.
- The Australian patent remains enforceable through 2027, offering licensing opportunities or freedom to operate for entities working in genetic testing.
Monitoring developments in the patent landscape will be critical, especially regarding similar gene signatures or detection technologies. Competitors must carefully chart overlapping claims and prior art to navigate freedom to operate.
Key Takeaways
- AU2007229866 protects gene expression-based diagnostics for breast cancer risk, with broad claims covering detection methods and gene sets.
- The patent landscape features heavily litigated areas, with overlapping patents like MammaPrint and Oncotype DX influencing market pathways.
- The patent's lifespan extends to 2027 in Australia, supporting commercial activities until then.
- Challenges may arise related to prior disclosures of similar gene signatures, potentially limiting enforceability.
- Successful market entry depends on designing around broad claims or licensing existing rights.
FAQs
Q1: Can the patent AU2007229866 be challenged based on prior scientific publications?
Yes. If prior publications disclose identical or similar gene expression signatures or detection methods, they could serve as prior art invalidating key claims.
Q2: Does the patent cover all gene expression-based breast cancer tests?
No. Its claims are limited to specific gene sets and detection methods detailed in the claims; tests using different signatures or technologies may circumvent the patent.
Q3: Is there potential for licensing or partnership?
Yes. Given the patent's scope and remaining term, licensing opportunities exist for companies developing or commercializing breast cancer genetic tests in Australia.
Q4: How does the patent compare to international counterparts?
The AU patent aligns with international applications focusing on gene expression signatures but is narrower in scope than broad patents like MammaPrint, which encompass larger gene panels and utility claims.
Q5: What are the risks associated with infringement in Australia?
Infringement risks exist if a product or method falls within the scope of the claims. Due to broad claim language, infringing detection may require careful analysis of the specific gene sets and detection techniques used.
References:
- Australian Patent AU2007229866. (2007). Method of diagnosing or predicting the onset of a disease.
- MammaPrint patent family. (n.d.). Genomic signature for breast cancer prognosis.
- Oncotype DX patent portfolio. (n.d.). Gene signature for breast cancer recurrence prediction.
